Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE
Type
Retraction
Notice date
8/21/2020 0:00
Journal
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology